Posts

Showing posts matching the search for 2 million people worldwide

In the Gig Economy, Coworking Spaces Are Everywhere—What Is It Like to Work in One? - Features

Image
The Riveter: This one was my favorite. Steve Korn S eattle has the fourth-fastest- growing freelance economy in the country, which explains why there are almost as many coworking spaces opening up as luxury apartment buildings . Since I'll never be able to afford a luxury apartment , I thought maybe I can at least work at a place where the sink actually drains and the coffee is always fresh. So I checked out some coworking spaces and brought my laptop with me. I didn't tell them I was coming. I wanted to see what these places were like inside, without any PR hoopla. Clearly, we are living in the age of the remote worker. By 2020, 40 percent of the US workforce will be freelancers, temps, independent contractors, or "solopreneurs," according to a 2010 study by Intuit. According to the 2017 Global Coworking Survey , nearly 1. 2 million people worldwide will have tried coworking by the end of next year, and around 14, 000 coworking spaces will be in operation. Sixt...

Clinical trials need more minorities

Image
At her 33rd appearance as Subject 16019 in a clinical trial of an experimental drug she hoped would fix "this little problem with my memory," Sandra Brannon sank into a medical exam room 's recliner and waited. "What's the date again?" Sandra asked me. I had escorted her to a wing at Bellevue Hospital Center in Manhattan, where the NYU Langone Medical Center was among 210 institutions worldwide conducting the trial. As a family friend, I was standing in for Sandra's only child and chief caregiver, who had business elsewhere that morning. "November 18th," I answered. I'd responded to the same question from Sandra four times during our 27- minute subway ride to a stop a few blocks from Bellevue. "Right. Got it." Sandra scribbled my reply on her cheat sheet as a nurse bounded through the door to prep her for her monthly intravenous infusion of solanezumab, which Eli Lilly developed to target mild cognitive impairment caused ...